Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12164847 | 0.86 | S1PR4 (0.52) | MAPTS1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL29693563 | 0.82 | ALDH1A1 (0.67) | MAPTALDH1A1FFAR1KDM4EGAA | |
| SCHEMBL371996 | 0.82 | ALDH1A1 (0.67) | MAPTALDH1A1FFAR1KDM4EGAA | |
| SCHEMBL9885402 | 0.79 | S1PR1 (0.58) | MAPTS1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4656709 | 0.78 | MAPT (0.64) | MAPTS1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL30890031 | 0.78 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL3036107 | 0.78 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL5371922 | 0.76 | ALDH1A1 (0.62) | MAPTS1PR1S1PR3ALDH1A1GAA | |
| SCHEMBL4403551 | 0.76 | POLB (0.62) | MAPTS1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL38657860 | 0.75 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2392565-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MAPT 4161/4885S1PR4 1903/4885S1PR1 2625/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MAPT 4161/4885S1PR4 1903/4885S1PR1 2625/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MAPT 4161/4885S1PR4 1903/4885S1PR1 2625/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | MAPT 4168/4885S1PR4 2534/4885S1PR1 2643/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | MAPT 4108/4885S1PR4 1798/4885S1PR1 2372/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | MAPT 4108/4885S1PR4 1798/4885S1PR1 2372/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MAPT 4118/4885S1PR4 1768/4885S1PR1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.